| 41.21 0.97 (2.41%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 48.86  |
1-year : | 57.07 |
| Resists | First : | 41.84 |
Second : | 48.86 |
| Pivot price | 37.31 |
|||
| Supports | First : | 36.28 |
Second : | 32.84 |
| MAs | MA(5) : | 38.86 |
MA(20) : | 36.58 |
| MA(100) : | 42.16  |
MA(250) : | 36.1 |
|
| MACD | MACD : | 1 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 92.5 |
D(3) : | 83.5 |
| RSI | RSI(14): 68.3 |
|||
| 52-week | High : | 62.2 | Low : | 16.45 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ BHVN ] has closed above the upper band by 2.2%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 21.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 41.87 - 41.99 | 41.99 - 42.13 |
| Low: | 40.38 - 40.53 | 40.53 - 40.7 |
| Close: | 40.94 - 41.17 | 41.17 - 41.43 |
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.
Thu, 09 May 2024
Biohaven Reports First Quarter 2024 Financial Results and Recent Business Developments - PR Newswire
Thu, 29 Feb 2024
Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments - PR Newswire
Tue, 14 Nov 2023
Biohaven Reports Third Quarter 2023 Financial Results and Recent Business Developments - PR Newswire
Thu, 29 Sep 2022
Biohaven's ALS drug fails to meet study goals - Reuters
Tue, 10 May 2022
Pfizer to Acquire Biohaven Pharmaceuticals - Business Wire
Tue, 10 May 2022
Pfizer to acquire Biohaven Pharma for $11.6 billion in cash sending Biohaven shares up 74% premarket - MarketWatch
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 88 (M) |
| Shares Float | 77 (M) |
| Held by Insiders | 12.8 (%) |
| Held by Institutions | 86.1 (%) |
| Shares Short | 9,850 (K) |
| Shares Short P.Month | 9,830 (K) |
| EPS | -6.91 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.68 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -65.3 % |
| Return on Equity (ttm) | -133.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -6.06 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -357 (M) |
| Levered Free Cash Flow | -214 (M) |
| PE Ratio | -5.98 |
| PEG Ratio | 0 |
| Price to Book value | 11.19 |
| Price to Sales | 0 |
| Price to Cash Flow | -10.2 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|